Ziprasidone and the Corrected QT Interval: A Comprehensive Summary of Clinical Data
CNS Drugs,  Clinical Article

Camm AJ et al. – The analyses provide the first comprehensive summary of QT interval (QTc) changes associated with ziprasidone based on Pfizer–sponsored phase II–IV randomized controlled trials (RCTs), safety reports and post–marketing surveillance. The results of the analyses of pooled data from phase II–IV RCTs in adults demonstrate a modest mean increase in QTc, infrequent QTc prolongation ≥60 ms and rare observation of QTc ≥480 ms. These data are consistent with results from ziprasidone clinical pharmacology studies, safety reports and post–marketing surveillance. Taken together, they provide the most comprehensive evidence published to date that ziprasidone appears to be safe when used as indicated in patients with schizophrenia or bipolar disorder.

Methods
  • The following analyses of data were conducted to obtain a comprehensive summary of QTc data on ziprasidone:
    • Post hoc analyses (using primarily descriptive statistics) of pooled QTc data (Fridericia correction) from more than 40 phase II-IV adult ziprasidone RCTs organized according to the following subgroups: all monotherapy studies in schizophrenia and bipolar disorder, all intramuscular (IM) studies, adjunctive studies in bipolar disorder and fixed-dose oral studies
    • Post hoc analyses from 36 phase II-IV adult ziprasidone RCTs exploring the relationship between QTc change from baseline and baseline QTc in adults
    • Post hoc analyses from phase II-IV adult ziprasidone RCTs modelling QTc change as a function of ziprasidone concentration in both adult (17 studies) and paediatric (5 studies) subjects
    • Cardiac adverse event (AE) reports from all phase II-IV adult ziprasidone RCTs in schizophrenia
    • A large simple trial entitled Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) in 18,154 subjects with schizophrenia (the only previously reported results included here); and
    • Cardiac-related AEs presented in a ziprasidone post-marketing surveillance report created in 2007.

Results
  • A total of 4306 adults received ziprasidone in placebo- and active-comparator phase II–IV RCTs and had evaluable QTc data.
  • One subject reached a QTc ≥480 ms; 33 (0.8%) had a QTc ≥450 ms.
  • QTc prolongation ≥30 ms was observed in 389 subjects (9.0%); ≥60 ms in 30 (0.7%); and ≥75 ms in 12 (0.3%).
  • In the placebo-controlled studies, mean change in QTc from baseline to end of study was 3.6 (± 20.8) ms in the ziprasidone group; the corresponding QTc change in the pooled placebo group was -0.3 (± 20.6) ms.
  • Data from IM studies, and bipolar studies in which ziprasidone was used adjunctively with lithium, valproate or lamotrigine, demonstrated similar QTc effects.
  • A scatter-plot of QTc prolongation against baseline QTc showed QTc prolongation ≥60 ms exclusively in adult subjects with a baseline QTc ≤400 ms.
  • The final concentration-response analysis model, comprising 2966 data points from 1040 subjects, estimates an increase in QTc of 6 ms for each 100 ng/mL increase in ziprasidone concentration.
  • The large simple trial (ZODIAC) failed to show that ziprasidone is associated with an elevated risk of non-suicidal mortality relative to olanzapine in real-world use.
  • Post-marketing data over a 5-year period did not show a signal of increased cardiac AEs.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Discontinuation of smokeless tobacco and mortality risk after myocardial infarction Circulation, July 25, 2014    Clinical Article

2 Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion Clinical Therapeutics, August 19, 2014    Clinical Article

3 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

4 Egg consumption and cardiovascular disease among diabetic individuals: a systematic review of the literature Full Text Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 30, 2014    Free full text    Review Article

5 Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease JACC - Journal of the American College of Cardiology, July 18, 2014

6 Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease The American Journal of Cardiology, August 28, 2014    Clinical Article

7 A statin a day to keep the doctor away? comparing aspirin and statins for primary prevention of cardiovascular disease Annals of Pharmacotherapy, August 7, 2014    Clinical Article

8 Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials The Journal of Clinical Hypertension, August 13, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 Drug-eluting stents versus coronary artery bypass grafting in diabetic patients with multi-vessel disease: a meta-analysis Heart, Lung, and Circulation, August 6, 2014    Evidence Based Medicine    Review Article

10 Efficacy and safety of pitavastatin versus simvastatin: A meta-analysis of randomized controlled trials Clinical Drug Investigation, August 4, 2014    Evidence Based Medicine    Review Article

11 Minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for single-vessel disease: A meta-analysis of 2885 patients European Journal of Cardio-Thoracic Surgery, August 14, 2014    Evidence Based Medicine    Review Article    Clinical Article

12 The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials Full Text BMC Cardiovascular Disorders, August 27, 2014    Free full text    Evidence Based Medicine    Review Article    Clinical Article

13 Statin use and mortality among blacks and whites in the Southeastern US Full Text Clinical Epidemiology, August 11, 2014    Free full text    Clinical Article

14 Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials Heart, Lung, and Circulation, August 8, 2014    Evidence Based Medicine    Review Article    Clinical Article

15 Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population American Heart Journal, July 29, 2014    Clinical Article

16 Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure Circulation: Heart Failure, July 24, 2014    Clinical Article

17 Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction Internal and Emergency Medicine, August 25, 2014    Clinical Article

18 Statins in the elderly: an answered question Current Opinion in Cardiology, June 9, 2014    Evidence Based Medicine    Review Article    Clinical Article

19 Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials The Lancet, August 20, 2014    Evidence Based Medicine    Clinical Article

20 Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria Journal of the Renin-Angiotensin-Aldosterone System, August 1, 2014    Clinical Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close